BioCryst 8-K Signals New Financial Disclosures on Jan 5

Ticker: BCRX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 882796

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, financial-condition, disclosure

TL;DR

**BioCryst just dropped an 8-K hinting at new financial info, watch for details.**

AI Summary

BioCryst Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024, related to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that the company likely disclosed material non-public information, possibly financial results or forward-looking statements, to a select audience before making it public. This matters to investors because it signals that new, potentially impactful information about the company's performance or outlook is now available, which could influence the stock price (BCRX) as the market digests these disclosures.

Why It Matters

This filing indicates BioCryst Pharmaceuticals (BCRX) has made new, potentially significant financial or operational disclosures, which could impact investor sentiment and stock valuation.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying event (disclosure of 'Results of Operations and Financial Condition') carries inherent risk as the content of those results is unknown and could be positive or negative.

Analyst Insight

Investors should look for the specific content of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' that BioCryst Pharmaceuticals (BCRX) made public on or around January 5, 2024, as this information will be key to understanding the company's current performance and outlook.

Key Players & Entities

FAQ

What was the specific 'earliest event reported' date in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 5, 2024.

What items of information were disclosed in this 8-K filing?

The 8-K filing disclosed information under 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'.

What is the trading symbol and the exchange where BioCryst Pharmaceuticals, Inc.'s common stock is registered?

BioCryst Pharmaceuticals, Inc.'s common stock trades under the symbol BCRX on the Nasdaq Global Select Market.

What is the business address of BioCryst Pharmaceuticals, Inc. as stated in the filing?

The business address of BioCryst Pharmaceuticals, Inc. is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.

What is the purpose of an 8-K filing related to 'Regulation FD Disclosure'?

An 8-K filing related to 'Regulation FD Disclosure' (Fair Disclosure) is used when a company has selectively disclosed material non-public information to certain individuals or groups, requiring them to make that information public simultaneously or promptly thereafter to ensure all investors have equal access.

Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 07:02:39

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 5, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing preliminary, unaudited ORLADEYO (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2023. The Company also provided guidance for full year 2024 ORLADEYO net revenue, full year 2024 operating expenses, expected peak ORLADEYO sales and an accelerated path to profitability. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2024 at 6:00 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. Effective January 8, 2024, the Company is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO in the United States from $40,348.60 per 28-day pack (of either 150mg or 110mg capsules) to $42,366.03 per 28-day pack (of either 150mg or 110mg capsules). The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 5, 2024 entitled "BioCryst Announces Preliminary Full Year 2023 ORLADEYO (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: January 8, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing